Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Never-smokers With Lung Adenocarcinoma
NCT01829217Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Started May 2013; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01829217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01829217.